AAM
ALXN

Ardevora Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Ardevora Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-122,523
Closed -$23.4M – 106
2015
Q4 		$23.4M Buy
122,523
+63,000
+106% +$11M 1.54% 2
2015
Q3 		$9.31M Buy
59,523
+13,800
+30% +$2.52M 1.35% 34
2015
Q2 		$8.27M Buy
45,723
+2,000
+5% +$345K 1.43% 4
2015
Q1 		$7.58M Buy
43,723
+600
+1% +$109K 1.44% 34
2014
Q4 		$7.98M Buy
+43,123
New +$7.99M 1.73% 28

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Ardevora Asset Management's ALXN Position: Q1 2016 in Review

Ardevora Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2016, closing a stake of 122,523 shares — an estimated $23.4M sold.

Ardevora Asset Management first reported a position in ALXN in Q4 2014 and held it in 5 quarters. The position peaked at $23.4M in Q4 2015. 518 funds tracked by Wall St. Rank hold ALXN as of Q1 2016.

  • Ardevora Asset Management reported no remaining Alexion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Ardevora Asset Management sold 122,523 Alexion Pharmaceuticals shares in Q1 2016, an estimated $23.4M.
  • Ardevora Asset Management first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 5 quarters.
  • Ardevora Asset Management's Alexion Pharmaceuticals position peaked at $23.4M in Q4 2015.
  • 518 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2016.

Based on Ardevora Asset Management's 13F filing for Q1 2016, filed 12 May 2016.